Trastuzumab Showed Improved Survival In Stage IV Breast Cancer with CNS Metastases
Majority of Invasive Bladder Cancer Patients Do Not Receive Full Recommended Care
Pertuzumab Delays Progression In HER2-Positive Breast Cancer
Sentinel Lymph Node Excision Has No Impact on Survival
Increased Breast Density Can Lead to Higher Risk
Computer Interpretation Software Does Not Improve Detection
Bone Marrow Transplant Survival Has Doubled In Young Patients
Two Studies Demonstrate Molecule Blocking Cell Damage
Interim Analysis Suggests Paclical Can Reduce Blood Levels
Hormone Therapy Can Reduce Survival In Men With Heart Problems
Zometa Can Reduce Risk Of Skeletal-Related Events
Cell Phone Radiation Does Not Raise Child’s Risk of Tumors
Clinical Trials Approved by NCI CTEP Last Month
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
